Investigation of TY-302 combined with abiraterone for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new investigational medicine (TY-302) combined with abiraterone, a standard hormone-blocking drug, in men with metastatic castration-resistant prostate cancer. It aims to see if this combination can slow cancer growth after initial hormone therapy stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer that has progressed after exactly one prior newer hormone therapy (like enzalutamide or apalutamide).
- You have not been treated with abiraterone before.
- Your testosterone level is low (≤50 ng/dL), either due to surgery or ongoing hormone-blocking treatment.
- You are 18 years or older and feel well enough to be up and about (ECOG 0 or 1).
- Your liver, kidney, and blood tests meet study safety thresholds.
- You have no active infections like HIV, hepatitis B or C, and no severe heart or lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.